期刊
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
卷 21, 期 3, 页码 323-337出版社
SPRINGER
DOI: 10.1016/j.jasms.2009.10.013
关键词
-
资金
- National Institutes of Health [R01 GM061666]
- National Science Foundation [CHF-0750389]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061666] Funding Source: NIH RePORTER
- Division Of Chemistry [0750389] Funding Source: National Science Foundation
Mass spectrometry plays a very visible role in biopharmaceutical industry, although its use in development, characterization, and quality control of protein drugs is mostly limited to the analysis of covalent structure (amino acid sequence and post-translational modifications). Despite the centrality of protein conformation to biological activity, stability, and safety of biopharmaceutical products, the expanding arsenal of mass spectrometry-based methods that are currently available to probe higher order structure and conformational dynamics of biopolymers did not, until recently, enjoy much attention in the industry. This is beginning to change as a result of recent work demonstrating the utility of these experimental tools for various aspects of biopharmaceutical product development and manufacturing, in this work, we use a paradigmatic protein drug interferon beta-1a as an example to illustrate the utility of mass spectrometry as a powerful tool not only to assess the integrity of higher order structure of a protein drug, but also to predict consequences of its degradation at a variety of levels. (J Am Soc Mass Spectrom 2010, 21, 323-337) (C) 2010 American Society for Mass Spectrometry
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据